Medicines safeguard clause: L rate set at −1% and W amount of €700m for hepatitis C
The 2015 Social Security Financing Act rewrites the contribution owed by pharmaceutical companies when their turnover from reimbursable medicines, net of rebates, grows faster than a rate L set by law. For 2015, L is set at −1%: the contribution is triggered as soon as turnover exceeds 99% of the previous year's. Orphan drugs with turnover below €30m and most generics are excluded. The same article sets at €700m, from 1 January 2015, the amount W above which hepatitis C treatments give rise to a specific contribution.
Measure originators
No official estimate found for this measure.
Measure impact
Applies to companies marketing reimbursed medicines. The contribution is due only if overall turnover exceeds the threshold; as an illustration, the impact assessment estimates that a 1% increase in reimbursed spending would yield a theoretical €132m. L and W were set for 2015; the mechanism was later replaced by an amount M in 2019.
Official references
Sources
Procedure timeline
Follow the progress of this fiscal measure through the different stages of the parliamentary procedure.
Administrative implementation
Entrée en vigueur de la mesure et mise en œuvre par l'administration
President of the Republic signature
Publication au Journal officiel
Possible referral to Constitutional Council
Décision de conformité / censure partielle